Indication
Fibrosis
17 clinical trials
15 products
2 drugs
Clinical trial
TRANSFORM: A 24-week, Randomized, Placebo-controlled, Double-blind, Phase 2b Trial of Setanaxib in Patients With Primary Biliary Cholangitis (PBC) and Elevated Liver StiffnessStatus: Active (not recruiting), Estimated PCD: 2024-07-06
Product
PlaceboProduct
SetanaxibClinical trial
Multicenter, Open-label Prospective Cohort Study of the Efficacy and Safety of the Inclusion of Longidaze in the Prevention and Treatment of Post-inflammatory Pulmonary Fibrosis and Interstitial Lung Diseases Caused by COVID-19.Status: Completed, Estimated PCD: 2022-04-20
Product
Bovhyaluronidase AzoxymerClinical trial
A Multi-Cohort, Randomised, Placebo-Controlled Phase 2a Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Ascending Doses of RXC007 in Patients With Idiopathic Pulmonary FibrosisStatus: Recruiting, Estimated PCD: 2024-04-01
Product
RXC007Clinical trial
A Phase I, Double Blind, Randomized, Placebo-controlled, Multiple Ascending Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Orally Administered 'Ivaltinostat' Capsule in Healthy Male VolunteersStatus: Active (not recruiting), Estimated PCD: 2023-12-01
Product
IvaltinostatClinical trial
A Randomised, Double-blind, Placebo-controlled, SAD/MAD First-in-human, Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of RXC007 Including Evaluation of Drug-Drug Interaction and Food Effect in Male ParticipantsStatus: Completed, Estimated PCD: 2023-03-08
Product
CC-90001Clinical trial
A Phase 2, 24-Week, Randomized, Double-blind, Placebo-controlled, Multicenter Study, With an 80-Week Active Treatment Extension, to Evaluate the Efficacy and Safety of CC-90001 in Subjects With Idiopathic Pulmonary FibrosisStatus: Terminated, Estimated PCD: 2021-12-24
Product
Saroglitazar MagnesiumClinical trial
A Phase 2b, Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy and Safety of Saroglitazar Magnesium in Subjects With Nonalcoholic Steatohepatitis and FibrosisStatus: Recruiting, Estimated PCD: 2025-07-01
Clinical trial
Effects of Empagliflozin on Preventing Fibrosis and Cirrhosis Progression in Nucleos(t)Ide Analogue-treated Chronic Hepatitis B Patients With Significant/Advanced Fibrosis or Cirrhosis: a Randomized, Double-blind Placebo-controlled TrialStatus: Recruiting, Estimated PCD: 2025-12-31
Product
EmpagliflozinClinical trial
An Open-lable Trial of Subcutaneous Semaglutide in Systemic SclerodermaStatus: Recruiting, Estimated PCD: 2024-08-29
Product
SemaglutideClinical trial
Use of Bevacizumab in Trabeculectomy Surgery. A Prospective, 2 Centre, Randomized, Controlled TrialStatus: Completed, Estimated PCD: 2013-09-01
Drug
AtezolizumabDrug
VarlilumabClinical trial
Semaglutide Treatment in the Real-world for Fibrosis Due to NAFLD in Obesity and T2DMStatus: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
68Ga-DOTA/NOTA-FAPI PET/CT in Patients With Various Fibrotic DiseaseStatus: Recruiting, Estimated PCD: 2024-04-01
Product
68Ga-FAPI-04Clinical trial
Liver Fibrosis in Zambian HIV-HBV Co-infected Patients: a Long-term Prospective Cohort StudyStatus: Active (not recruiting), Estimated PCD: 2024-08-01
Product
Anti-HIV AgentsClinical trial
Growth Hormone as a Model for Reversible Activation of Adipose Tissue FibrosisStatus: Active (not recruiting), Estimated PCD: 2023-12-31
Product
PegvisomantClinical trial
A Phase 2B, Randomized, Multi-Center, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rencofilstat in Adult Subjects With Nonalcoholic Steatohepatitis and Advanced Liver FibrosisStatus: Active (not recruiting), Estimated PCD: 2025-05-01
Product
RencofilstatClinical trial
Multicenter, Randomized, Double-blind, Placebo-controlled Parallel-group Study to Evaluate the Efficacy and Safety of Longidaza® for the Treatment of Patients With Residual Changes in the Lungs After COVID-19Status: Completed, Estimated PCD: 2023-12-31
Product
Longidaza®Clinical trial
A Phase 1, Randomized, Double Blinded, Placebo Controlled, First-in Human Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses and Multiple Ascending Doses of RSN0402 in Healthy VolunteersStatus: Not yet recruiting, Estimated PCD: 2024-12-27
Product
RSN0402